We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Published in Renal Cell Carcinoma

Journal Scan / Review · March 01, 2021

Immune Checkpoint Inhibitors + Tyrosine Kinase Inhibitors for the Treatment of RCC

Expert opinion on biological therapy

 

Additional Info

Expert opinion on biological therapy
Combination of Immune Checkpoint Inhibitors and Tyrosine Kinase Inhibitors for the Treatment of Renal Cell Carcinoma
Expert Opin Biol Ther 2021 Feb 12;[EPub Ahead of Print], V Stühler, S Rausch, JM Maas, A Stenzl, J Bedke

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading